Department of Pharmacology, NeuroSearch A/S, 93 Pederstrupvej, DK-2750 Ballerup, Denmark.
Neuropharmacology. 2011 Jul-Aug;61(1-2):121-32. doi: 10.1016/j.neuropharm.2011.03.017. Epub 2011 Mar 31.
After injury GABA(A) receptor positive allosteric modulators (PAMs) mediate robust analgesia in animals via putative restoration of post-synaptic GABA(A)-α2 and -α3 receptor function within the spinal cord. GABA can also act at GABA(A) receptors localized on primary afferent neurones to inhibit presynaptic neurotransmitter release and produce analgesia via a process called primary afferent depolarization (PAD). Some forms of injury might sufficiently enhance PAD to shift it into a net excitatory process. Thus, negative allosteric modulators (NAMs) might also possess analgesic activity. We have compared compounds capable of either positively or negatively modulating GABA(A) receptors in rat models associated with injury-induced central sensitization. The subtype-selective PAMs NS11394 (1-10 mg/kg) and TPA023 (3-30 mg/kg) attenuated formalin-induced nocifensive behaviours. Similarly, both compounds reversed hindpaw mechanical hypersensitivity and weight bearing deficits in carrageenan-inflamed and nerve-injured rats. The non-selective PAM diazepam (1-5 mg/kg) was ineffective in all models. Surprisingly, both the non-selective NAM FG-7142 (3-30 mg/kg) and the α5-selective NAM α5IA-II (10-60 mg/kg) also attenuated formalin-induced nocifensive behaviours. In carrageenan-inflamed rats α5IA-II reversed mechanical hypersensitivity and weight bearing deficits whilst FG-7142 only attenuated weight bearing deficits. This picture was essentially reversed in nerve-injured rats for these two NAMs. With the exception of NS11394, all compounds attenuated exploratory motility behaviour in rats, either as a consequence of sedative or anxiogenic-like side-effects. These data indicate that the preferred selectivity and activity profiles for mediating analgesia upon activation of GABA(A) receptors might be more complex than previously anticipated, and is worthy of further exploration.
受伤后,GABA(A) 受体正变构调节剂(PAMs)通过假定在脊髓内恢复突触后 GABA(A)-α2 和 -α3 受体功能,在动物中介导强大的镇痛作用。GABA 还可以作用于位于初级传入神经元上的 GABA(A) 受体,抑制突触前神经递质释放,并通过称为初级传入去极化(PAD)的过程产生镇痛作用。某些形式的损伤可能会充分增强 PAD,使其转变为净兴奋过程。因此,负变构调节剂(NAMs)也可能具有镇痛活性。我们比较了在与损伤诱导的中枢敏化相关的大鼠模型中能够正向或负向调节 GABA(A) 受体的化合物。亚型选择性 PAMs NS11394(1-10mg/kg)和 TPA023(3-30mg/kg)减弱了福尔马林诱导的伤害性行为。同样,两种化合物都逆转了角叉菜胶炎症和神经损伤大鼠的后爪机械性超敏和负重缺陷。非选择性 PAM 地西泮(1-5mg/kg)在所有模型中均无效。令人惊讶的是,非选择性 NAM FG-7142(3-30mg/kg)和α5 选择性 NAM α5IA-II(10-60mg/kg)也减弱了福尔马林诱导的伤害性行为。在角叉菜胶炎症大鼠中,α5IA-II 逆转了机械性超敏和负重缺陷,而 FG-7142 仅减轻了负重缺陷。对于这两种 NAMs,在神经损伤大鼠中,这种情况基本相反。除 NS11394 外,所有化合物都减弱了大鼠的探索性运动行为,这要么是镇静作用的结果,要么是焦虑样副作用的结果。这些数据表明,激活 GABA(A) 受体介导镇痛作用的首选选择性和活性谱可能比以前预期的更为复杂,值得进一步探索。